LEIOMYOSARCOMA

This study tests whether adding lurbinectedin to standard chemotherapy (doxorubicin) helps people with metastatic leiomyosarcoma live longer without their cancer growing. About 455 adults who have not had prior treatment for advanced disease will receive either the combo or doxor…

This study tests whether combining two drugs, rucaparib and nivolumab, can shrink or control advanced leiomyosarcoma (LMS), a rare soft-tissue cancer. About 20 adults with LMS that cannot be removed by surgery or has spread will receive the treatment. The goal is to see if this c…

This study tests an experimental cell therapy called tabelecleucel in 190 people with diseases caused by the Epstein-Barr virus (EBV), including certain cancers and post-transplant complications. The goal is to see if the treatment can shrink tumors and improve survival. Particip…

This early-stage study tests whether adding an experimental drug (BO-112) to an immunotherapy (nivolumab) before surgery is safe for people with soft tissue sarcoma that can be removed. The goal is to see if this combination can boost the immune system to better attack the cancer…

This study tests a virus-based drug (T-VEC) combined with radiation for adults with newly diagnosed soft tissue sarcoma that can be removed by surgery. The goal is to see if this combination can destroy most of the tumor before surgery and to check for side effects. About 40 peop…

This study tests whether adding the drug pazopanib to standard radiation or chemoradiation helps shrink soft tissue sarcomas before surgery. About 140 patients with newly diagnosed, removable tumors took part. The goal is to see if the combination is safe and improves tumor respo…

This study tests two different drug combinations in people with advanced colorectal, pancreatic, or leiomyosarcoma cancers that have not responded to standard treatments. Participants receive either olaparib plus durvalumab or cediranib plus durvalumab. The main goal is to unders…